July 30, 2016 1:12 AM ET

Capital Markets

Company Overview of Johnson & Johnson Innovation - JJDC, Inc.

Company Overview

Johnson & Johnson Innovation - JJDC, Inc. operates as a private equity and venture capital arm of Johnson & Johnson. The firm specializes in investments from early stages of seed funding including start-up, early, mid, and late venture investments to the advanced stages of series venture management. It also provides bridge financing. The firm invests in emerging health care businesses and life science and technology businesses that focus on traditional health care sectors such as medical devices, diagnostics, consumer health, pharmaceuticals, and consumer products, as well as emerging areas of innovation, including biotechnology, and wellness and prevention. Within pharmaceuticals and biotec...

410 George Street

New Brunswick, NJ 08901

United States

Founded in 1973

Phone:

732-524-3218

Fax:

732-247-5309

Key Executives for Johnson & Johnson Innovation - JJDC, Inc.

President
Vice President of Venture Investments and Chief Operating Officer
Vice President of Venture Investments
Vice President of Venture Investments
Vice President of Venture Investments
Compensation as of Fiscal Year 2016.

Johnson & Johnson Innovation - JJDC, Inc. Key Developments

Astrazeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JDJC, Inc. and Imperial College London, University College London and the University of Cambridge Join Forces to Create the Apollo Therapeutics Fund; Appoints Ian Tomlinson as Chairman of Apollo Therapeutics Investment Committee

AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc. and Imperial College London, University College London and the University of Cambridge have joined forces with a combined £40 million to create the Apollo Therapeutics Fund (‘Apollo’). This pioneering new joint venture will support the translation of ground-breaking academic science from within these universities into innovative new medicines for a broad range of diseases. Each of the three industry partner companies (AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc.) will contribute £10 million over 6 years to the venture. The technology transfer offices (TTOs) of the three university partners - Imperial Innovations Group plc, Cambridge Enterprise Ltd. Limited and UCL Business PLC - will each contribute a further £3.3 million. The aim of Apollo is to advance academic preclinical research from these universities to a stage at which it can either be taken forward by one of the industry partners following an internal bidding process or be out-licensed. The three industry partners will also provide R&D expertise and additional resources to assist with the commercial evaluation and development of projects. Drug development is extremely complex, costly and lengthy; currently only around 10% of therapies entering clinical trials reach patients as medicines. By combining funding for promising early-stage therapeutics from leading UK universities with a breadth of industry expertise, Apollo aims to share the risk and accelerate the development of important new treatments, while also reducing the cost. Dr. Ian Tomlinson, former Senior Vice President, Worldwide Business Development and Biopharmaceuticals R&D, for GSK and founder & Chief Scientific Officer of Domantis Limited has been appointed Chairman of the Apollo Therapeutics Investment Committee. Comprising representatives from the six partners, the AIC will make all investment decisions.

Johnson & Johnson Innovation - JJDC, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 through Jan-13-2016

Johnson & Johnson Innovation - JJDC, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-11-2016 through Jan-13-2016. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States. Presentation Date & Speakers: Jan-11-2016, Guy Seabrook, VP, Neuroscience Innovation. Jan-12-2016, Ed Torres, Managing Partner.

Johnson & Johnson Innovation - JJDC, Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015

Johnson & Johnson Innovation - JJDC, Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: Sep-16-2015, Ibraheem Badejo, Senior Director, New Ventures, Kuldeep Neote, Senior Director, New Ventures/Scout, V. Kadir Kadhiresan, Vice President of Venture Investments.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
13D Research (USVI) LLC. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Fund Raising
June 14, 2016
Gilde Healthcare IV
Private Placement
April 5, 2016
Tesaro, Inc.
Private Placement
April 5, 2016
RefleXion Medical Inc.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Johnson & Johnson Innovation - JJDC, Inc., please visit www.jjdevcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.